Real-world outcomes of anthracycline and taxane-based perioperative breast cancer therapy using the Japanese electronic medical record database
Japanese Journal of Clinical Oncology · 13.02.2026 · 56 (2) · 130-138
DOI: 10.1093/jjco/hyaf177 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 21.11.2025. Verfasst von Masaaki Kawai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery I, Yamagata University Graduate School of Medical Science, 2-2-2, Iida-nishi, Yamagata, Yamagata, 990-9575, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Anthracyclines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anthracycline (A) and taxane (T)-based therapies improve breast cancer survival, with guidelines strongly recommending these regimens and dose-dense approaches. However, the real-world maintenance of optimal dose intensity, a critical prognostic factor, remains unclear. We aimed to clarify the current treatment situation regarding relative dose intensity (RDI), with a secondary focus on safety.
Methods
In this retrospective observational study, we analyzed big data from the DATuM IDEA® electronic medical record database of the Japan Medical Association Medical Information Management Organization, collected from 1 206 955 individuals across 53 medical institutions throughout Japan over 57 months since 2019. We focused on women with primary breast cancer receiving adriamycin/cyclophosphamide (AC), epirubicin/cyclophosphamide (EC), or docetaxel/cyclophosphamide chemotherapy (TC).
Results
Analysis included 1989 women who received at least two courses of AC, EC, or TC perioperatively. Patients received 2-weekly adriamycin/cyclophosphamide (ddAC) (n = 207), 3-weekly AC (AC q3w) (n = 177), 2-weekly epirubicin/cyclophosphamide (ddEC) (n = 269), 3-weekly EC (EC q3w) (n = 684), and TC (n = 652). Pegfilgrastim was administered to 98% of ddAC/ddEC, 38% of AC q3w, 42% of EC q3w, and 74% of TC patients. Grade 4 neutropenia (incidences >20%) was observed in AC q3w patients aged ≥65 years (22.6%) and in TC patients of any age (27.6%). RDI remained >95% in all groups.
Conclusions
RDI was high in all groups. Clinicians should be cautious when administering AC q3w therapy owing to the high likelihood of patients developing Grade 4 neutropenia. For TC, a slightly lower pegfilgrastim administration rate and >20% Grade 4 neutropenia suggest the need for appropriate pegfilgrastim use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery I, Yamagata University Graduate School of Medical Science, 2-2-2, Iida-nishi, Yamagata, Yamagata, 990-9575, Japan.
- TOPPAN Holdings Inc. 1-3-3, Suido, Bunkyo-ku, Tokyo, 112-8531, Japan.
ORCID-Profile: Masaaki Kawai, Fuyuhiko Motoi
Zitieren
APA
Kawai, M., Kazato, T., Kiyosaki, W., Matsuura, S., & Motoi, F. (2026). Real-world outcomes of anthracycline and taxane-based perioperative breast cancer therapy using the Japanese electronic medical record database. Japanese Journal of Clinical Oncology, 56(2), 130-138. https://doi.org/10.1093/jjco/hyaf177
Vancouver
Kawai M, Kazato T, Kiyosaki W, Matsuura S, Motoi F. Real-world outcomes of anthracycline and taxane-based perioperative breast cancer therapy using the Japanese electronic medical record database. Japanese Journal of Clinical Oncology. 2026;56(2):130-138. doi:10.1093/jjco/hyaf177
BibTeX
@article{Kawai2026,
author = {Kawai, Masaaki and Kazato, Tomoko and Kiyosaki, Wakana and Matsuura, Shigeru and Motoi, Fuyuhiko},
title = {Real-world outcomes of anthracycline and taxane-based perioperative breast cancer therapy using the Japanese electronic medical record database},
journal = {Japanese Journal of Clinical Oncology},
year = {2026},
volume = {56},
number = {2},
pages = {130--138},
doi = {10.1093/jjco/hyaf177}
}
EUVIMED